Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
The Lancet. Healthy Longevity|September 13, 2022
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trialMatthias P Ebert, Nadja M Meindl-Beinker, Tobias Gutting, et al.
Cancer Immunology Research|November 11, 2024
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and ImmunotherapyJoseph Tintelnot, Lisa Paschold, Eray Goekkurt, et al.
JAMA Oncology|June 23, 2022
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical TrialAlexander Stein, Lisa Paschold, Joseph Tintelnot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2023
Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I TrialBeate Rau, Hauke Lang, Alfred Koenigsrainer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 TrialSylvie Lorenzen, Thorsten Oliver Götze, Peter Thuss-Patience, et al.
The New England Journal of Medicine|January 22, 2025
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal CancerJens Hoeppner, Thomas Brunner, Claudia Schmoor, et al.
Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.
Pageof 7